Message from Steve on Nov 14 1996 6:00PM EST
Robert,
Thanks for the info on Yale's patent.
Although this is great news, the market has yet to acknowledge.
In otherwords, a buying opportunity. I believe the same antiviral agent may be
effective against HIV as well!
This will help VION attract addtional capital and move it closer to having real
products for sale (although FDA approval is a long way off).
What impresses me most about the company is the lineup of products in various
stages of development. Assuming additional progress on VION's TAPET is made
and announced, this is a 10-bagger.
//////////////////////////////////////////////////
This company was born on hype associated with a patent application for 3TC and a radiation sensitizer for which compostion of matter and "use" patents were not available. Upon inspection, it turned out that the 3TC claims were not just only an application, but it was also a U.S.-only situation where protection in the remainder of the world was not a viable opportunity. That is, these guys were promoting crap while making the fine print difficult to find.
I haven't followed them since the OncoRx to Vion rebirth. All the patents in the world from Yale on nucleotides/nucleosides won't change the fact that they are _way_ behind and competing with Glaxo, Gilead Sciences, and others. Next-generation nucleosides, including PMPA, are rolling into the clinic big-time for both HBV and HIV. Has anyone approached VION to license the molecules from Yale?
Steve...... could you provide more info re. the "microorganisms" involved with TAPET? In general, could you fill us in to a greater degree regarding TAPET? Is there some sort of formal mechanism for funneling Yale projects to VION, or has it occured on an investigator-by-investigator basis? Does Yale have an equity position in VION? Also, in an earlier post, you mentioned you and your Ph.D. buddies. Is your background molecular?
Thanks, Rick |
